ZLY18 explained
| Legal Status: | Investigational |
| Cas Number: | 2642392-33-2 |
| Stdinchi: | 1S/C25H23FO6/c1-29-20-8-5-17(6-9-20)3-4-18-11-21(30-2)14-22(12-18)31-15-19-7-10-24(23(26)13-19)32-16-25(27)28/h3-14H,15-16H2,1-2H3,(H,27,28)/b4-3+ |
| Stdinchikey: | QASIQJGISCBDLW-ONEGZZNKSA-N |
| Smiles: | COc1ccc(cc1)C=Cc2cc(OC)cc(c2)OCc3ccc(c(F)c3)OCC(=O)O |
| Iupac Name: | 2-[2-Fluoro-4-[[3-methoxy-5-[(1''E'')-2-(4-methoxyphenyl)ethenyl]phenoxy]methyl]phenoxy]acetic acid |
| C: | 25 |
| H: | 23 |
| F: | 1 |
| O: | 6 |
ZLY18 is an experimental drug that acts as an agonist of the free fatty acid receptor 1 (FFA1) and all three types of peroxisome proliferator-activated receptor (alpha, delta, and gamma). It is in development for the treatment of non-alcoholic fatty liver disease.[1] [2] [3] [4]
Notes and References
- Zhou . Zongtao . Ren . Qiang . Jiao . Shixuan . Cai . Zongyu . Geng . Xinqian . Deng . Liming . Wang . Bin . Hu . Lijun . Zhang . Luyong . Yang . Ying . Li . Zheng . Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents . European Journal of Medicinal Chemistry . 5 February 2022 . 229 . 114061 . 10.1016/j.ejmech.2021.114061 . 34954593 . 245394392 . 1768-3254.
- Xu . Xiaohan . Poulsen . Kyle L. . Wu . Lijuan . Liu . Shan . Miyata . Tatsunori . Song . Qiaoling . Wei . Qingda . Zhao . Chenyang . Lin . Chunhua . Yang . Jinbo . Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) . Signal Transduction and Targeted Therapy . 2022 . 7 . 1 . 287 . 10.1038/s41392-022-01119-3 . 35963848 . 9376100 . en . 2059-3635.
- Gong . Lijun . Wei . Fang . Gonzalez . Frank J. . Li . Guolin . Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines . Hepatology . 2023 . 78 . 5 . 1625–1653 . 10.1097/HEP.0000000000000182. 36626642 . 255593877 . 10681123 .
- Statham . Laura . Pelling . Melina . Hanson . Petra . Kyrou . Ioannis . Randeva . Harpal . Barber . Thomas M . Designer GLP1 poly-agonist peptides in the management of diabesity . Expert Review of Endocrinology & Metabolism . 4 May 2023 . 18 . 3 . 231–240 . 10.1080/17446651.2023.2204976. 37089108 . 258268432 . free .
